FDG-PET,a Complementary Modality to Computed Tomography in Radiotherapy Target Volume Delineation for Head and Neck CancerVoichita Bar-Ad1*, Wenyin Shi1, Madalina Tuluc2, Nitin Ohri1, David Cognetti3, Joseph Curry3 and Charles Intenso4
- *Corresponding Author:
- Dr. Voichita Bar-Ad
MD, Department of Radiation Oncology
Thomas Jefferson University 111 S. 11th Street
Philadelphia, PA 19107, USA
E-mail: [email protected]
Received date: January 09, 2012; Accepted date: February 21, 2012; Published date: February 24, 2012
Citation: Bar-Ad V, Shi W, Tuluc M, Ohri N, Cognetti D, et al. (2012) FDG-PET, a Complementary Modality to Computed-Tomography in Radiotherapy Target Volume Delineation for Head and Neck Cancer. J Nucl Med Radiat Ther 3:124. doi: 10.4172/2155-9619.1000124
Copyright: © 2012 Bar-Ad V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objectives: The objective of the current review was to use published data to assess the role of [18F] fluorodeoxyglucose-positron emission tomography (FDG-PET) as a complementary modality to computedtomography (CT) in radiotherapy target volume delineation for head and neck cancer (HNC).
Methods: Studies were identified by searching PubMed electronic databases. Both prospective and retrospective studies were included. Information regarding the role of FDG-PET for radiotherapy target volume delineation for HNC was analyzed.
Results: FDG-PET is a promising tool for improving radiotherapy target volume delineation by defining a metabolically active biological target volume (BTV). The use of novel PET tracers representing properties such as hypoxia, protein synthesis and proliferation remain to be better characterized.
Conclusions: The role of FDG-PET for radiotherapy target volume delineation for patients with HNC is expanding and should be further evaluated in clinical trials.